Clovis Oncology, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.9Mgeneral payments (2019-2025)
$18Kresearch payments (2019-2025)
4,373clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Keith Flaherty | Boston, MA | $917,649.19 | |
| Joshua Kesterson | Newport, PA | Gynecologic Oncology | $122,578.45 |
| Lyndsay Willmott | Phoenix, AZ | Gynecologic Oncology | $98,042.43 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $90,129.86 |
| John Chan | San Francisco, CA | Gynecologic Oncology | $82,697.96 |
| Robert Morris | Detroit, MI | Gynecologic Oncology | $53,794.11 |
| Amer Karam | Stanford, CA | Gynecologic Oncology | $51,268.70 |
| Scott Richard | Florham Park, NJ | Gynecologic Oncology | $50,473.59 |
| Kristopher Lybarger | Kansas City, MO | Gynecologic Oncology | $40,964.79 |
| Chirag Shah | Seattle, WA | Gynecologic Oncology | $40,228.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.